Eli Lilly and Company (LLY · NYSE)

LLY · MARKET VIEW

Market view · as of Aug 31, 2026

Revenue (TTM)
$79.67B
+47.7% YoY
Gross margin
83.4%
EPS (latest q)
$8.38
vs $6.01 est · beat
52-wk position
81.5%
-8.3% vs 52w high · +2.4% 1mo

Price (last ~year)

Eli Lilly and Company (LLY) shares opened 3.57% lower on August 26, reflecting investor profit-taking and concerns regarding obesity treatment reimbursement. Despite this volatility, the company maintains a $1.05 trillion market capitalization, supported by 47.7% year-over-year revenue growth and $79.67 billion in trailing twelve-month revenue. The firm has exceeded earnings estimates for four consecutive quarters, reporting $7.09 billion in net income for the period ending June 30, 2026.

Valuation

Market cap
$1.05T
P/E
39.52
PEG
1.479
P/B
30.94
P/S
13.15
EV/EBITDA
26.24
Beta
0.506
Analyst target
$1315.04

Quality & returns

Gross margin
83.4%
Operating margin
54.2%
Profit margin
33.5%
ROE
102.3%
ROA
20.4%

Price movement

Last
$1174.61
1-month
+2.4%
3-month
+9.0%
RSI (14)
40
vs SMA200
+11.2%
52-wk position
81.5% -8.3% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$22.97B$8.98B$7.09B$9.25B
2026-03-31$19.80B$8.85B$7.40B$9.69B
2025-12-31$19.29B$8.78B$6.64B$8.39B
2025-09-30$17.60B$8.39B$5.58B$7.88B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots